Trial Profile
A Phase I Open-Label, Non-Randomized, Dose-Escalation Study of rSIFN-co in Subjects With Advanced Solid Tumors and With an Expansion Cohort at Recommended Dose (RD) in Subjects With Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma, Hepatocellular Carcinoma or Colon Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs RSIFN-co (Primary)
- Indications Colon cancer; Colorectal cancer; Liver cancer; Malignant melanoma; Nasopharyngeal cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sichuan Huiyang Life Science and Technology Corporation
- 25 Sep 2019 Status changed from recruiting to completed.
- 10 Dec 2015 According to ClinicalTrials.gov record, the primary end point has been amended.
- 10 Dec 2015 Planned number of patients changed from 36 to 42, according to ClinicalTrials.gov record.